ArticleVascular health and risk management2025
Association of the Coagulation Factor V c.3865T>G Mutation with Genetic and Regional Susceptibility to Cerebral Venous and Sinus Thrombosis in Xiangyang.
Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates the potential genetic and regional associations of a newly identified c.3865T>G mutation in the F5 gene (coagulation factor V) with cerebral venous and sinus thrombosis (CVST). Methods: Two groups of CVST cases associated with hereditary thrombophilia were analyzed. Genetic sequencing was performed to identify the patients' genetic profiles. A family pedigree analysis and a review of relevant literature were conducted to assess the pathogenic significance of the mutation. Results: Genetic analysis revealed the presence of a c.3865T>G mutation in the F5 gene in both cases. This mutation is distinct from the well-established Leiden mutation and has not been previously reported. Although the two patients' families had no direct blood relationship, both patients resided in the same geographic region, suggesting the possibility of shared environmental or genetic factors. Advances in diagnostic technologies have also facilitated the identification of hereditary thrombophilia as an increasingly recognized cause of CVST. Conclusion: The c.3865T>G mutation in the F5 gene may represent a novel genetic contributor to CVST. Its regional clustering points to a potential genetic and geographic association. These findings provide new insights into the etiology and diagnosis of CVST and underscore the importance of investigating regional genetic predispositions further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.